Copy
View this email in your browser
State and Federal Overview: the Novel Coronavirus (COVID-19), May 13, 2020
International
WHO has published an annex to the guidance on considerations on adjusting public health and social measures (PHSM). The new annex provides a pragmatic decision process to help countries through adapting PHSM based on epidemiological and public health criteria. According to the 2020 World Health Statistics published by WHO today, the COVID-19 pandemic is causing significant loss of life, disrupting livelihoods, and threatening the recent advances in health and progress towards global sustainable development goals. WHO has joined forces with the United Kingdom to run an awareness campaign named “Stop The Spread” about the risks of inaccurate and false information regarding the COVID-19 pandemic. The Regional Director for the WHO Regional Office for the Americas, Dr. Carissa F. Etienne called on countries to “support their economies while building strong social protection networks and embracing evidence-based public health measures that are essential to saving lives”. In the ‘Subject in Focus’, we discuss newly released WHO guidelines for school-related public health measures.
   
Federal Government
U.S. Cases - Provided by the New York Times
Total Cases: 1.3 million+
Deaths: 83,818
 
Includes confirmed and probable cases where available.
 
Congressional Budget Office
Answers Related to Federal Funding for State and Local Governments
This letter answers questions and answers related to federal funding for state and local governments.

Medicaid
The first set of questions was about the effects of the 2020 coronavirus pandemic on Medicaid. The sharp rise in unemployment caused by the pandemic will increase enrollment in the program. Many of the new enrollees will have experienced sudden declines in income, and some will have become sick because of the pandemic. Some would otherwise have been covered by employment-based health insurance or nongroup coverage subsidized through premium tax credits. Some would otherwise have been uninsured but with too much income to be eligible for Medicaid. Others would have been eligible for Medicaid but nevertheless unenrolled. New enrollees may sign up on their own or be enrolled by providers at the point of service.
 
In addition to health care costs ordinarily covered by Medicaid, states may opt to have the program cover the costs of testing for the disease caused by the coronavirus, COVID-19, for some uninsured people. (The federal government will cover all of those costs.)
 
Later this year, CBO will report updated baseline budget projections for Medicaid that incorporate effects of the pandemic, as well as the increased share of Medicaid expenses covered by the federal government this year (a change put in place by last month’s CARES Act). For the remainder of 2020, CBO expects state governments to pay 35 percent of Medicaid’s costs, on average, for most enrollees; the average in 2019 was 41.5 percent. For other enrollees, adults made eligible for the program by the Affordable Care Act, the CARES Act did not change the share of Medicaid’s costs to be paid by state governments; that share remains 10 percent.
 
Budget Shortfalls
The second set of questions was about the effects of shortfalls in the budgets of state and local governments caused by the pandemic. State and local governments will collect less revenue because of the sudden drop in economic activity and resulting fall in taxable income in 2020. It is unclear how large those shortfalls will be.
 
At the same time, demand for social services provided by state and local governments will increase. In the 2007–2009 recession and subsequent recovery, state and local governments similarly experienced fiscal pressure. They responded mainly by reducing spending on education, health, and social services. Some of those reductions were achieved by cutting public-sector employment.
 
On May 19, CBO will report interim economic projections for 2020 and 2021 that incorporate effects of the pandemic. As part of that work, CBO will provide its usual projection of growth in gross domestic product and its components, including growth attributable to purchases by state and local governments. That projection will take into account the expected effects of the pandemic on states’ budgets.
 
Economic Effects of Federal Funding for State and Local Governments
The third set of questions was about how spending during recessions by state and local governments has affected the economy in the past and how the effects of such spending compare with the effects of other policies that federal lawmakers are considering today.
 
The federal government can boost economic output in various ways, including by providing funds to state and local governments. In the current economic environment, CBO expects, additional amounts of such funding would increase output by reducing the size of tax increases and spending cuts enacted by many of those jurisdictions to balance their budgets. The tax increases avoided and services provided would help residents in the short term. Providing such funds to state and local governments would, however, increase the federal deficit, and in the long term, increased federal deficits tend to slow the economy, in CBO’s assessment.
 
CBO estimates that each additional dollar that was used to fund state and local governments by increasing the federal deficit would increase economic output over the next few years by about as much as would a dollar used to fund some policies recently enacted in the CARES Act. Such policies included funding provided to state governments for pandemic-related expenses and increases in unemployment benefits. The economic effects of increases in unemployment benefits depend on factors such as economic conditions, the type of increase, and the amount of the benefit relative to people’s potential earnings, in CBO’s assessment. The effects of additional expansions of unemployment insurance would therefore differ from those stemming from the CARES Act. For example, as social distancing dissipated, the per-dollar boost to the economywide demand for goods and services would be larger; and as the labor market strengthened, the reduction in the supply of labor per dollar of unemployment insurance benefits would be larger. The net effect on output of such factors would depend on the specific types of additional expansions.
 
Other provisions of the CARES Act, such as increases in federal spending on Medicare, are expected to have larger effects on the economy. Still other provisions, such as business tax provisions and refundable tax credits, are expected to have smaller effects— although the size of the effects would depend on the specifics of the provisions and the corresponding extent to which businesses and households spent the funds they received. And in addition to having different effects on output, policies in the CARES Act are expected to have different effects on other outcomes—such as employment and the distribution of income—and effects that vary by sector of the economy, geographic location, and demographic group.
 
Broadly speaking, CBO expects the CARES Act to support the economy in ways similar to those provided by the American Recovery and Reinvestment Act (ARRA), which was enacted in 2009; the agency’s estimates are informed by research about that experience. That said, stay-at-home orders, other aspects of social distancing, and other factors are expected to lead to some differences in the impact of particular policies in 2020 as compared with 2009.
 
The funding for state governments provided by ARRA for purposes other than infrastructure totaled over $200 billion. In its analysis of ARRA, CBO projected that each dollar of such funding had a two-thirds chance of increasing output by an amount between $0.40 and $1.80 over two years. That estimate used averages of effects from many different uses of the funds. In addition, ARRA provided about $60 billion for spending on infrastructure—specifically, on water, transportation, and housing projects— and CBO projected that each of those dollars had a two-thirds chance of increasing output by an amount between $0.40 and $2.20.
 
Spending for Purposes Other Than Infrastructure. CBO anticipates that the availability of additional funds would both increase states’ net spending for any specified activities and also affect other aspects of states’ budgets. Without further funding from the federal government, states’ tax increases or spending cuts would be larger than they would be otherwise because of fiscal constraints, including requirements to balance their budgets, CBO expects; those actions would result from fiscal challenges arising from the pandemic and also from preexisting challenges, such as unfunded pension liabilities. Such actions would dampen spending by those governments and by households in those states, and more state and private jobs would be lost. Furthermore, many states would probably have to take such steps on an ongoing basis during the next few years.
 
Therefore, federal funding that was provided promptly would probably have a significant effect on output and employment. Such funding could lead states and localities to lay off fewer employees, hire more of them, give them more pay raises, impose fewer pay cuts, purchase more goods and services, spend more on safety-net programs, or impose lower taxes than they would without the funding. But some of the funding would probably be used to replenish or avoid drawing down states’ reserve funds; funding used in that way would not boost the economy in the short term.
 
Spending for Infrastructure. Infrastructure spending directly increases employment because workers are hired to undertake construction projects. It also adds to demand for goods and services through purchases of material and equipment and through additional spending by the extra workers who are hired; that increase in demand leads to further hiring. However, government spending on infrastructure projects could also cause private-sector spending on infrastructure projects to fall. In addition, CBO projects that there is a two-thirds chance that states would reduce spending of their own funds on infrastructure by between $0.20 and $0.80 for each one-dollar increase in federal outlays for that purpose. Also, over the long term, spending on infrastructure can affect productivity, with effects that can differ substantially depending on the type of project.
 
Infrastructure projects often involve considerable start-up lags. Although some projects (such as highway repair and resurfacing) can be implemented relatively quickly, large-scale construction projects generally require years of planning and preparation. For example, building new transportation infrastructure that requires establishing new rights-of-way or developing and implementing alternative energy sources would probably have their biggest effects on output and employment after a few years. Indeed, trying to increase certain types of spending too quickly would raise the risk of making poor decisions about what specific projects should be supported. As a practical matter, the experience with ARRA suggests that the spending of infrastructure funds is slow: By the end of fiscal year 2009, seven and a half months after the legislation was enacted, less than 10 percent of the infrastructure funds provided by ARRA had been spent. Access the document here.
U.S. Centers for Disease Control and Prevention
CDC's Laboratory Outreach Communication System (LOCS) (CDC’s gateway to interact with U.S. clinical laboratories). The Laboratory Outreach Communication System (LOCS) is managed by the Division of Laboratory Systems (DLS) in the Center for Surveillance, Epidemiology, and Laboratory Services (CSELS). Currently, LOCS is a functional CDC mailbox (LOCS@cdc.gov) designed to provide updates and answer questions from clinical laboratories through coordination with professional organizations, CDC programs, and state public health laboratories.
 
The mailbox is managed and monitored by DLS staff and is active during regular business hours. Information and updates are sent to clinical laboratories through professional organizations. This system is available to other CDC programs and may also be used during emergency responses to disseminate information in collaboration with CDC’s Joint Information Center in the Emergency Operations Center.
Lab Advisory: CDC Posts Updated Point-of-Care Testing Biosafety Guidelines for COVID-19.  CDC recently updated the Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019 (COVID-19) to provide additional information about point-of-care (POC) testing for SARS-CoV-2. This update includes guidance for a variety of topics:
  • Use of instruments in a location associated with a current CLIA certificate
  • Site- and activity-specific risk assessment
  • Proper training for staff
  • Adherence to Standard Precautions when handling clinical specimens
  • Decontamination of the POC instruments
Online resources:
U.S. Centers for Medicare & Medicaid Services
CMS Issues Nursing Homes Best Practices Toolkit to Combat COVID-19. Today, under the direction of President Trump, CMS released a new toolkit developed to aid nursing homes, Governors, states, departments of health, and other agencies who provide oversight and assistance to these facilities, with additional resources to aid in the fight against the coronavirus disease 2019 (COVID-19) pandemic within nursing homes. The toolkit builds upon previous actions taken by the Centers for Medicare & Medicaid Services (CMS), which provide a wide range of tools and guidance to states, healthcare providers and others during the public health emergency. The toolkit is comprised of best practices from a variety of front line health care providers, Governors’ COVID-19 task forces, associations and other organizations, and experts, and is intended to serve as a catalogue of resources dedicated to addressing the specific challenges facing nursing homes as they combat COVID-19. Press release.
U.S. Department of Health and Human Services
HHS Awards $15 Million to Support Telehealth Providers During the COVID-19 Pandemic
Today, the U.S. Department of Health and Human Services (HHS), through the Health Resources and Services Administration (HRSA) awarded $15 million to 159 organizations across five health workforce programs to increase telehealth capabilities in response to the COVID-19 pandemic. These awards demonstrate the Trump Administration’s continued efforts and commitment to building a national telehealth infrastructure.
 
These awards are funded through the Coronavirus Aid, Relief and Economic Security (CARES) Act that President Trump signed into law on Friday, March 27, 2020. HRSA made awards to organizations based on their capacity to implement COVID-19 telehealth activities that train high demand professions across the health care team.
 
These investments will train students, physicians, nurses, physician assistants, allied health and other high-demand professionals in telehealth. This will enable these professionals to maximize telehealth for COVID-19 referrals for screening and testing, case management, outpatient care, and other essential care during the crisis.
 
Additionally, through increased telehealth capabilities from this funding, organizations will be able to maintain primary care services when clinics and medical facilities are not available, especially for COVID-19 positive, quarantined, elderly and other vulnerable populations.
 
HRSA’s Bureau of Health Workforce (BHW) oversees the workforce programs that received awards today. The five BHW programs that received funding are:
  • Geriatrics Workforce Enhancement Program
  • Area Health Education Centers Program
  • Centers of Excellence Program
  • Nurse Education, Practice, Quality and Retention – Veteran Nurses in Primary Care Training Program
  • Nurse Education, Practice, Quality and Retention – Registered Nurses in Primary Care Training Program
View the complete list of today’s award recipients.
 
FY2020 COVID-19 Workforce Telehealth Awards
 
Geriatrics Workforce Enhancement Program
HRSA awarded $4,350,000 to 48 grantees.
View Geriatrics Workforce Enhancement Program award details
 

Area Health Education Centers Program
HRSA awarded $4,200,020 to 44 grantees.
View Area Health Education Centers Program award details
 

Centers of Excellence Program
HRSA awarded $2,700,000 to 18 grantees.
View Centers of Excellence Program award details
 

Nurse Education, Practice, Quality and Retention
 
Registered Nurses in Primary Care Training Program
HRSA awarded $3,299,982 to 42 grantees. 
View Registered Nurses in Primary Care Training Program award details
“COVID-19: Safely Getting Back to Work and Back to School”
Witnesses appearing before the Senate Health, Education, Labor and Pensions Committee: The Department of Health and Human Services (HHS) is working closely with all of our government partners in this response.  We thank Congress for supporting our efforts through the passage of the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; the Families First Coronavirus Response Act; the Coronavirus Aid, Relief, and Economic Security (CARES) Act; and the Paycheck Protection Program and Health Care Enhancement Act.  These laws have provided additional resources, authorities, and flexibility. Within HHS, the Centers for Disease Control and Prevention (CDC), the National Institute of Allergy and Infectious Diseases (NIAID), the Assistant Secretary for Health, and the Food and Drug Administration (FDA), along with additional components not represented today, play critical roles in the response to this public health emergency as discussed by the following witnesses:
  • Anthony Fauci, MD Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
  • Robert Redfield, MD, Director, United States Centers for Disease Control and Prevention, Atlanta, GA.
  • ADM Brett Giroir, MD, Assistant Secretary for Health, United States Department of Health and Human Services, Washington, DC.
  • Stephen Hahn, MD, Commissioner of Food and Drugs, United States Food and Drug Administration, Silver Spring, MD. 
U.S. Food and Drug Administration
The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:
  • The FDA took important actions to help accelerate the development of prevention and treatment options for COVID-19 by providing new guidance with recommendations for innovators and researchers conducting work in this area. These guidance documents aim to make the process for submitting applications to initiate studies for new drugs and biological products more efficient by outlining recommendations for ways to design clinical trials to evaluate safety and effectiveness of these medical products for COVID-19.
  • The FDA provided an update on surveillance inspections during the COVID-19 pandemic. In the update, the agency stated it will continue to utilize and implement additional alternative inspection tools and approaches while postponing domestic and foreign routine surveillance inspections. This will continue as local, national and international conditions warrant, with the exception of certain mission critical inspections. 
  • The FDA issued a warning letter to one company that was selling fraudulent COVID-19 products, as part of the agency’s effort to protect consumers. The seller warned, Fusion Health and Vitality LLC, recently offered products, including “CORE” and “IMMUNE SHOT,” for sale in the U.S. with claims that misleadingly represented the products as safe and/or effective for the prevention and treatment of COVID-19. There are currently no FDA-approved products to prevent or treat COVID-19. Consumers concerned about COVID-19 should consult with their health care provider.
  • The FDA posted updated information for blood establishments regarding COVID-19, which aligns with the agency’s guidance on convalescent plasma to allow donation 14 days after complete resolution of symptoms. The posting also provides updated information blood establishments may wish to consider when evaluating prospective blood donors.
  • Yesterday, the FDA issued an Emergency Use Authorization (EUA) for the Ascom teleCARE IP Nurse Call System for use by healthcare providers and patients in healthcare environments, including temporary hospital facilities, to facilitate remote communication between patients and healthcare providers. The remote communication and monitoring capabilities of the teleCARE IP Nurse Call System may reduce the amount of contact by healthcare providers with patients who are in isolation rooms, thereby reducing healthcare provider risk of exposure to SARS-CoV-2, the virus that causes COVID-19.
  • Yesterday, FDA issued an EUA for the emergency use of the Eko electrocardiogram (ECG) Low Ejection Fraction Tool (“ELEFT”) to be used by healthcare professionals to provide an assessment of Left Ventricular Ejection Fraction as a diagnostic aid to screen for potential cardiac complications associated with COVID-19 or underlying cardiac conditions that may affect clinical management of COVID-19, in adult patients having or suspected of having COVID-19. The EUA was issued to Manatt, Phelps & Philips.
  • Testing updates to date:
    • During the COVID-19 pandemic, the FDA has worked with more than 500 test developers who have said they will be submitting EUA requests to the FDA for tests that detect the virus.
    • To date, FDA has authorized 93 tests under EUAs, which includes 12 antibody tests and 1 antigen test.
Federal Emergency Management Agency (FEMA)
Feds to Support COVID-19 Testing Sites in Texas through June 30
In conjunction with U.S. Dept. of Health and Human Services and the state of Texas, the Federal Emergency Management Agency (FEMA) announced today, the seven federally supported COVID-19 Community-Based Testing Sites (CBTS) in Texas will remain open through June 30, 2020. The sites will continue monitoring and testing citizens in an effort to reduce further spreading of the virus.
 
The seven CBTSs, which are federally supported, state managed and locally executed, are located in El Paso County, Dallas County (2), and Harris County (4) are operated in conjunction with HHS and the state of Texas. Read the full release here.
National Institutes of Health
National Institutes of Health: What's New in the Treatment Guidelines (Last Updated: May 12, 2020)
 
New Section of the Guidelines
Antithrombotic Therapy in Patients with COVID-19. COVID-19 has been associated with inflammation and a prothrombotic state, with increases in fibrin, fibrin degradation products, fibrinogen, and D-dimers. Although the true incidence of thrombosis is unknown, there have been reports of increased incidence of thromboembolic disease associated with COVID-19 in patients in the intensive care unit.

A new section titled Antithrombotic Therapy in Patients with COVID-19 has been added to the guidelines to address many questions related to the role of coagulation markers and thrombolytic, anticoagulant, and antiplatelet agents in those with COVID-19. In this section, the COVID-19 Treatment Guidelines Panel (the Panel) provides recommendations on the use of antithrombotic agents for the prevention of venous thromboembolic events in hospitalized patients with COVID-19. In addition, the Panel recommends carefully monitoring, evaluating, and treating hospitalized patients with COVID-19 for incident thrombotic events when indicated.
 
Updates to the Guidelines. Potential Antiviral Drugs Under Evaluation for the Treatment of COVID-19. Throughout the section, study descriptions were updated to clearly indicate a study’s publication status and to provide an assessment of a study’s limitations and results. Data were also updated as needed based on changes to preprints or post-publication changes.
 
The following recommendations were added or revised in this section:

Remdesivir:
  • On the basis of preliminary clinical trial data, the Panel recommends the investigational antiviral agent remdesivir for the treatment of COVID-19 in hospitalized patients with severe disease, defined as SpO2 ≤94% on ambient air (at sea level), requiring supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (BI).
    • Remdesivir is not approved by the Food and Drug Administration (FDA); however, it is available through an FDA emergency use authorization for the treatment of hospitalized adults and children with COVID-19. Remdesivir is also being investigated in clinical trials, and it is available through an emergency access program for children and pregnant patients.
  • The Panel does not recommend remdesivir for the treatment of mild or moderate COVID-19 outside the setting of a clinical trial (AIII).
Chloroquine/Hydroxychloroquine:
  • The Panel recommends against using high-dose chloroquine (600 mg twice daily for 10 days) for the treatment of COVID-19 (AI), because the high dose carries a higher risk of toxicities than the lower dose.
  • The FDA warning that cautioned against the use of chloroquine or hydroxychloroquine for COVID-19 outside the setting of a hospital or clinical trial was added to this section.
Immune-Based Therapy Under Evaluation for Treatment of COVID-19 The following key changes were made to this section:
 
Convalescent Plasma and Immune Globulins:
  • New information has been added to the section on convalescent plasma and SARS-CoV-2-specific immune globulins.
  • A new section for non-SARS-CoV-2 intravenous immune globulin (IVIG) was created, in which the Panel recommends against the use of non-SARS-CoV-2-specific IVIG for the treatment of COVID-19, except in the context of a clinical trial (AIII). This should not preclude the use of IVIG when it is otherwise indicated for the treatment of complications that arise during the course of COVID-19.
Interleukin-6 Inhibitors:
  • New data from an interim review of a Phase 2/3 clinical trial for sarilumab have been included.
  • New preliminary results from a clinical trial for tocilizumab (CORIMUNO-TOCI) have been added.
  • There is no change to the Panel’s recommendation for IL-6 inhibitors. There are insufficient data to recommend either for or against the use of IL-6 inhibitors (e.g., sarilumab, siltuximab, tocilizumab) for the treatment of COVID-19 (AIII).
The State of Texas
From the Office of the Governor, Greg Abbott
Governor Abbott, TDEM Announce Extension of Federally-Supported Community-Based Testing Sites In Texas. Governor Greg Abbott and the Texas Division of Emergency Management (TDEM) today announced that the federal government has extended seven community-based testing sites in Texas through June 30, 2020. These federally-supported, state-managed, and locally-executed sites include El Paso (1), Dallas (2), Houston (2), and Harris County (2). Read the full release here.
Governor Abbott, Texas National Guard Launch Disinfection Mission for Nursing Facilities. Governor Greg Abbott today announced that the Texas National Guard has activated Facilities Disinfection Teams to support Texans in nursing homes and to help limit the spread of COVID-19. These Facilities Disinfection Teams, formed in coordination with Texas Health and Human Services Commission (HHSC), provide a major boost to protecting Texans and limiting the spread of COVID-19. Six teams have already been mobilized to facilities across the state with more coming online.  
 
These Facilities Disinfection Teams consist of Guardsmen from Joint Task Force 176, and each team is equipped with unique supplies such as advanced personal protective equipment, ionized sprayers, and vital oxide. The teams received training from the Texas Military Department 6th Civil Support Team, who specialize in man-made and natural disaster assessment and rapid response in hazardous environments.  
 
The Texas National Guard is currently supporting the fight against COVID-19 in Texas by providing personal protective equipment manufacturing support, food bank support, mobile COVID-19 testing, and points of distribution for essential items. Read the full release here.
Governor Abbott Waives License Renewal Late Fees for Certain Occupational Licenses in Texas. Governor Greg Abbott has waived license renewal late fees that accrued between March 13 and June 15, 2020 for occupational licenses issued by the Texas Department of Licensing and Regulation (TDLR). This waiver applies to licenses associated with a variety of occupations such as barbers, cosmetologists, electricians, speech-language pathologists, and dyslexia therapists. Read the full release here.
Texas Department of Licensing and Regulation (TDLR)
Texas Department of Licensing and Regulation (TDLR) Provides Further Clarification of Massage Therapy Services Allowed. Under the Governor’s Executive Order GA-21 (GA-21), massage establishments must remain closed until further notice. GA-21 also prohibits people from providing services which are not designated as essential or re-opened, including massage therapy.
 
GA-21 designates healthcare providers, including physicians and chiropractors, as essential. It does not include massage therapists, unless they are providing services determined to be medically necessary by a physician, chiropractor, or other healthcare provider. Massage therapy that is not medically necessary is still not allowed. If a licensed massage therapist performs a medically necessary massage, they must do so in accordance with the massage therapy laws and rules, including the requirement of a consultation document. A medically necessary massage may be performed in the office of a physician or chiropractor or any other place that is exempt from the requirement for a massage establishment license under Texas Occupations Code §455.155.
 
Please note that GA-21 overrides conflicting local orders, and the ability to provide massage therapy may change as further orders are issued.
Health Care
Department of State Health Services
COVID-19 Case Count. The Texas Department of State Health Services (DSHS) is working closely with the Centers for Disease Control and Prevention (CDC) in responding to the new coronavirus disease 2019 (COVID‑19) that is causing an outbreak of respiratory illness worldwide. State case counts, current as of 3:20 PM can be found by accessing the DSHS COVID-19 Dashboard.
 
Health and Human Services Commission
GL 20-3004 Emergency Rule for Outpatient Chemical Dependency Treatment Services via Electronic Means to Adolescents and Adults in Chemical Dependency Treatment Facilities (CDTFs) Available Online. GL 20-3004 (PDF) regarding adoption of emergency rules related to CDTFs providing outpatient chemical dependency treatment services via electronic means to adults and adolescents has been posted. The emergency rule permits CDTFs to temporarily provide treatment services via electronic means to clients to reduce the risk of transmission of COVID-19. Contact Health Care Regulation’s Policy, Rules and Training unit with your questions.
HHSC Publishes CMS Notification of More Blanket Waivers for ICFs
CMS is providing more blanket waivers related to care for residents in intermediate care facilities for individuals with an intellectual disability or related conditions. Waivers were issued in the following area:
 
Specific Life Safety Code (New since April 30). CMS is waiving and modifying waivers under §483.470(j) for ICF/IIDs:
  • Alcohol-based Hand-Rub Dispensers. CMS is waiving the prescriptive requirements for the placement of ABHR dispensers for use by staff and others due to the need for the increased use of ABHR in infection control. Refer to: 2012 LSC, sections 18/19.3.2.6.
  • Fire Drills. Quarterly fire drills move and mass staff together preventing proper distancing. Therefore, CMS will permit a documented orientation training program for the current fire plan, which considers current facility conditions.  The training will instruct employees, including existing, new or temporary employees, on their current duties, life safety procedures and the fire protection devices in their assigned area. Refer to: 2012 LSC, sections 18/19.7.1.6.
  • Temporary Construction. CMS is waiving requirements that would otherwise not permit temporary walls and barriers between patients. Refer to: 2012 LSC, sections 18/19.3.3.2.
Labor and Unemployment
The Texas Workforce Commission released the agency’s Labor Market Review for April which reflects March job numbers. 
 

Total Nonagricultural Wage and Salary employment in Texas contracted over the month for the first time in more than two and a half years, shedding 50,900 jobs in March. This represented the fifth largest over-the-month decline in series history beginning in 1990. Private sector employment dropped by 54,300 jobs which contributed to the smallest annual increase since September 2017. Employment in seven of 11 major industries declined over the month. The Total Nonfarm annual growth rate decreased by 0.4 percentage points from 2.4 percent in February to 2.0 percent in March.

Highlights

  • Leisure and Hospitality lost the most jobs of all major industries in March, posting a series high decline of 25,900 jobs. Accommodation and Food Services accounted for the majority of this loss with a decrease of 25,000 positions.
  • The Manufacturing industry shed 7,600 jobs over the month, which marked the largest drop since July 2009. Durable Goods employment fell by 3,000 jobs while Non- Durable jobs fell by 4,600 in March.
  • The Financial Activities industry tied for the most monthly jobs added among major industries with 3,400 positions in March.

Read the full publication Texas Labor Review | Access Texas Labor Highlights
CAP Website
EWA Facebook
CAP LinkedIn
CAP Twitter

Copyright © 2018 Congress Avenue Partners, All rights reserved.
Your are receiving this email because you have indicated your interest in receiving regular reports from Congress Avenue Partners.

Our mailing address is:
816 Congress Avenue #701
Austin, Texas 78701

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list

 






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
Congress Avenue Partners · 1604 San Antonio St. · Austin, TX 78701 · USA